Skeel`s Handbook of Cancer Therapy-9판

For more than 30 years, Skeel's Handbook of Cancer Therapy (formerly Handbook of Cancer Chemotherapy) has been the
resource of choice for current, reliable information on cancer treatment for most adults.
The 9th Edition reflects recent significant advances in the systemic treatment of cancer, including innovations in
immunotherapy, oncology genomics, and molecular targeted therapy.

An invaluable reference for all levels of physicians, nurses, and allied health professionals who provide care to
cancer patients, this bestselling guide combines the most current rationale and the details necessary to safely
administer pharmacologic therapy, offering a balanced synthesis between science and clinical practice.

* A new chapter on the Biologic Basis of Molecular Targeted Therapy, as well as a state-of-the-art review of the
current development and use of novel immunotherapeutics, bring you up to date with the rationale and use of these newer
agents in cancer treatment.

* Completely updated throughout to reflect current best practices, including primary indications, usual dosage and
schedule, special precautions, and expected toxicities for dozens of new drugs and biologic agents.

* New contributors provide a fresh perspective on timely topics in cancer treatment and care.

* An updated section on supportive care reflects this essential aspect of the oncology team's focus.

* Regularly updated Inkling content keeps you current with drug profiles and new immunotherapy advances.Now with the
print edition, enjoy the bundled interactive eBook edition, which can be downloaded to your tablet and smartphone or
accessed online and includes features like:

* Complete content with enhanced navigation

* Powerful search tools and smart navigation cross-links that pull results from content in the book, your notes, and
even the web

*Cross-linked pages, references, and more for easy navigation

*Highlighting tool for easier reference of key content throughout the text

* Ability to take and share notes with friends and colleagues

* Quick reference tabbing to save your favorite content for future use

Section I: Basic Principles and Considerations of Rational Chemotherapy and Molecular Targeted Therapy
Chapter 1: Biologic and Pharmacologic Basis of Cancer Chemotherapy
I. General Mechanisms by Which Chemotherapeutic Agents Control Cancer
Figure 1.1
II. Tumor Cell Kinetics and Chemotherapy
Figure 1.2
Table 1.1: Examples of Cell Cycle Phase뻊pecific Chemotherapeutic Agents
Table 1.2: Examples of Cell Cycle뻊pecific and Cell Cycle뻅onspecific Chemotherapeutic Agents
III. Combination Chemotherapy
IV. Resistance to Antineoplastic Agents
References
Chapter 2: Biologic Basis of Molecular Targeted Therapy
I. Introduction
Table 2.1
II. Function-Directed Therapy
III. Phenotype-Targeted Therapy
References
Chapter 3: Principles of Cancer Immunotherapy
I. Introduction
II. Anticancer Immune Responses
III. Toxicity and Management of Toxicity
IV. Response Kinetics
V. Predictive Biomarkers and Patient Selection
VI. Clinical Activity and Application
References
Chapter 4: Systematic Assessment of the Patient With Cancer and Consequences of Treatment
I. Establishing the Diagnosis
II. Staging
III. Performance Status
Table 4.1: Karnofsky Performance Status Scale
Table 4.2: ECOG/WHO/Zubrod Performance Status Scale
IV. Response to Therapy
V. Toxicity
VI. Late Physical Effects of Cancer Treatment
Acknowledgments
References
Chapter 5: Selection of Treatment for the Patient With Cancer
I. Setting Treatment Goals
II. Choice of Cancer Treatment Modality
III. Palliative Care
References
Section Ii: Medical Therapies of Human Cancer
Chapter 6: Carcinomas of the Head and Neck
I. Introduction
Figure 6.1
Table 6.1: Response Rate for Combination Chemotherapy Agents in Recurrent HNC
References
Chapter 7: Carcinoma of the Lung
I. Introduction
II. Etiology
III. Molecular Biology
IV. Screening
V. Non뻊mall-Cell Lung Cancer
Table 7.1: Randomized Studies of Adjuvant Chemotherapy for Resected NSCLC
Table 7.2: Chemotherapy Regimens for Concurrent Chemoradiation for Stage III NSCLC
Table 7.3: Common Frontline Regimens for Metastatic NSCLC
VI. Small-Cell Lung Cancer
Table 7.4: Chemotherapy Regimens for SCLC
References
Chapter 8: Carcinomas of the Gastrointestinal Tract
I. Introduction
II. Carcinoma of the Esophagus
III. Gastric Carcinoma
IV. Cancer of the Small Intestine
V. Cancer of the Large Intestine
VI. Cancer of the Anal Canal
References
Chapter 9: Carcinomas of the Pancreas, Liver, Gallbladder, and Bile Ducts
I. Adenocarcinoma of the Pancreas
II. Pancreatic Neuroendocrine Tumors (PNETs)
III. Carcinoma of the Bile Ducts (Cholangiocarcinoma) and Gallbladder Carcinoma
IV. Primary Carcinoma of the Liver
References
Chapter 10: Carcinoma of the Breast
I. Natural History and Modes of Treatment
II. Systemic Therapy of Breast Cancer
Table 10.1: Prognostic Factors for Assessing Risk of Recurrence of Breast Cancer
Figure 10.1
Acknowledgments
References
Chapter 11: Gynecologic Cancer
I. Cervical Cancer
Table 11.1: Gynecologic Oncology Group (GOG) 240 Bevacizumab Arm Regimens
II. Endometrial Cancer
Table 11.2: Chemotherapy Regimens for Endometrial Cancer
III. Uterine Sarcomas
IV. Ovarian Cancer
Table 11.3: Chemotherapy Regimens for Ovarian Cancer
V. Vulvar Cancer
VI. Ovarian Germ Cell Tumors
VII. Stromal or Granulosa Cell Tumors
VIII. Gestational Trophoblastic Neoplasm
Table 11.4: Prognostic Scoring Index for Gestational Trophoblastic Tumors
Table 11.5: Multiagent Chemotherapy Regimens for Gestational Trophoblastic Disease
References
Chapter 12: Urologic and Male Genital Cancers
I. Urothelial Cancer
Table 12.1: Common Chemotherapy Regimens for Cancer of the Bladder
II. Prostate Cancer
III. Testicular Cancer (Germ-Cell Tumors)
IV. Penile Cancer
References
Chapter 13: Kidney Cancer
I. Renal Cell Carcinoma (RCC)
Table 13.1: Hereditary Renal Cell Carcinoma Syndromes
Table 13.2: UISS Staging for Patients with Localized Disease
Table 13.3: MSKCC Risk Stratification for Metastatic Disease
Table 13.4: Treatment in Metastatic Renal Cell Carcinoma-Clear Cell Type
II. Treatment for Non-Clear Cell Carcinoma
References
Chapter 14: Endocrine Cancers
I. Thyroid Carcinoma
Table 14.1: MACIS Prognostic Scoring System for Thyroid Cancer
II. Adrenocortical Carcinoma
III. Pheochromocytoma and Paraganglioma
References
Chapter 15: Melanomas and Other Cutaneous Malignancies
I. Introduction
II. Melanoma
Table 15.1: Clark Levels of Invasion
Table 15.2: Approximate Survival in Melanoma Based on Stage Grouping
Table 15.3: Multiagent Systemic Therapy for Melanoma
III. Nonmelanoma Skin Cancer
Acknowledgments
References
Chapter 16: Primary and Metastatic Brain Tumors
I. Primary Brain Tumors
Table 16.1: Chemotherapy for Malignant Gliomas (Adjuvant)
Table 16.2: Regimens for Recurrent GBM
Table 16.3: Chemotherapy Regimens Used in PCNSL
II. Metastatic Brain Disease
III. Leptomeningeal Carcinomatosis (LMC)
Table 16.4: Chemotherapy Regimens for the Treatment of LMC
References
Chapter 17: Soft-Tissue Sarcomas
I. Epidemiology of Soft-Tissue and Visceral Sarcomas
Table 17.1: Examples of Molecular Subtypes of Sarcomas
II. Clinical Management of Soft-Tissue and Visceral Sarcomas
III. Conclusions
Acknowledgments
References
Chapter 18: Bone Sarcomas
I. Incidence and Nosology
II. Predisposing Factors for Bone Sarcoma
III. Clinical Symptoms and Diagnosis of Bone Sarcomas
Figure 18.1
IV. Staging
V. Osteosarcoma
VI. Chondrosarcoma
VII. Ewing Sarcoma
Figure 18.2
VIII. Other Histologic Subtypes of Primary Sarcoma of the Bone (Former Malignant Fibrous Histiocytoma of Bone)
IX. Giant Cell Tumor of the Bones
X. Chordomas
XI. Conclusions
Acknowledgments
References
Chapter 19: Acute Leukemias
I. General Features of Acute Leukemias
Table 19.1: Clinical and Laboratory Features of Acute Leukemia
Table 19.2: Antigens Commonly Demonstrated by Flow Cytometry Techniques
Table 19.3: WHO Classification of AML (Simplified)
Table 19.4: AML Prognostic Groups Based on Cytogenetic and Molecular Data at Presentation*
Table 19.5: WHO 2008 Classification of ALL
Table 19.6: Immunophenotypes of ALL
II. Initial Supportive Measures
III. Therapeutic Principles and Approach to the Therapy of Acute Leukemia
IV. Therapy for Adult AML (Other Than APL)
Table 19.7: Commonly Administered Induction Regimens in AML
Table 19.8: HiDAC Consolidation Regimens
Table 19.9: Prognostic Index for Younger Adults With AML in Relapse
Table 19.10: Some of the Novel and Investigational Agents Being Evaluated for the AML Therapy
V. Acute Promyelocytic Leukemia
Table 19.11: Adverse Prognostic Features in APL
Table 19.12: Management of Coagulopathy in APL
Table 19.13: Therapeutic Recommendations for APL
Table 19.14: Recommendations for Relapsed APL
VI. Therapy for Adult All
Exhibit 164
Exhibit 165
References
Chapter 20: Chronic Leukemias
I. Introduction
II. Chronic Myelogenous Leukemia
Table 20.1: WHO Criteria for Diagnosis of Accelerated and Blast Phase CML4
Table 20.2: Response Criteria in CML15,16
Table 20.3: Milestones and Definitions of Response to First-Line TKI16
Table 20.4: Allogeneic Stem-Cell Transplant and European Group for Blood and Marrow Transplantation Risk Score43
III. Chronic Lymphocytic Leukemia
Table 20.5: CLL Staging Systems47?9
Table 20.6: Staging and Prognosis in CLL
Table 20.7: Factors Associated with Poor Prognosis in CLL
Table 20.8: Response Criteria for CLL45
IV. Related B-Cell Leukemias
References
Chapter 21: Myeloproliferative Neoplasms and Myelodysplastic Syndromes
I. BCR-ABL1-Negative Myeloproliferative Neoplasms
Figure 21.1
Figure 21.2
II. Myelodysplastic Syndromes
Table 21.1: MDS Subtypes: FAB Classification
Table 21.2: 2008 WHO Classification of MDS and Pertinent Features
Table 21.3: IPSS for MDS
Table 21.4: The MD Anderson Scoring System for MDS
Table 21.5: Revised IPSS for MDS (IPSS-R)
Figure 21.3
Acknowledgments
References
Chapter 22: Hodgkin Lymphoma
I. Introduction
II. Pathology of HL
III. Diagnosis and Staging
Table 22.1: Cotswold Modification of the Ann Arbor Staging System for Hodgkin Lymphoma
IV. Treatment of HL
Table 22.2: Chemotherapy Regimens Used in the Treatment of Hodgkin Lymphoma
V. Initial Treatment by Stage of Disease
VI. Relapsed or Refractory HL
Table 22.3: Salvage Regimens in the Treatment of Hodgkin Lymphoma
VII. Follow-Up and Survivorship
References
Chapter 23: Non-Hodgkin Lymphoma
I. Introduction
II. Epidemiology and Risk Factors of NHL
Table 23.1: Geographical Distribution of Certain NHLs
Table 23.2: Factors Associated With an Increased Risk of NHL
Table 23.3: Immune-Related Conditions that Predispose to NHL
Table 23.4: Infectious Agents Associated With NHL
III. Classification of NHL
Table 23.5: WHO 2008 Classification of Lymphoid Neoplasms
IV. Staging of NHL
Table 23.6: Recommended Workup of Newly Diagnosed NHL
Table 23.7: Staging System for NHL
V. Prognosis of NHL
Table 23.8: International Prognostic Index for NHL
Table 23.9: Age-Adjusted International Prognostic Index for DLBCL*
Table 23.10: Follicular Lymphoma International Prognostic Index (FLIPI)
Table 23.11: F2 Prognostic Model
VI. Management of Indolent NHL
Table 23.12: Indolent Lymphoma Initial Treatment
Table 23.13: Staging System for Cutaneous T-Cell Lymphoma
VII. Management of Aggressive Lymphomas
Table 23.14: Mantle Cell Lymphoma International Prognostic Index
Table 23.15: Chemotherapy Regimens for Newly Diagnosed Mantle Cell Lymphoma
Table 23.16: Targeted Treatment of Relapsed Mantle Cell Lymphoma
Table 23.17: Chemotherapy Regimens for Aggressive B-NHL
Table 23.18: Treatment Options for PTCL
Table 23.19: CODOX-M/IVAC for Burkitt Lymphoma
VIII. Management of Highly Aggressive NHL
Table 23.20: Salvage Chemotherapy Regimens in Aggressive NHL
Table 23.21: Targeted Agents
Table 23.22: Risk Factors for PTLDs
References
Chapter 24: Multiple Myeloma, Other Plasma Cell Disorders, and Primary Amyloidosis
I. Introduction
II. Monoclonal Gammopathy of Uncertain Significance
III. Multiple Myeloma
Table 24.1: Diagnostic Criteria of MGUS and MM
Table 24.2: Durie-Salmon Staging System
Table 24.3: ISS System for Multiple Myeloma
Table 24.4: Uniform Response Criteria as Defined by the IMWG
IV. Waldenstr? Macroglobulinemia (Lymphoplasmacytic Lymphoma)
V. Amyloidosis
References
Chapter 25: Metastatic Cancer of Unknown Origin
I. Introduction
II. Diagnosis of Cups
Table 25.1: Baseline Assessments for Diagnosis of CUPs
Table 25.2: Key Screening Antibodies and Immunohistochemical Markers for the Identification of CUPs
Table 25.3: Cytokeratin Profile of Frequent Primary Cancers
References
Section Iii: Supportive Care of Patients with Cancer
Chapter 26: Side Effects of Chemotherapy
I. Introduction
II. Infusion-Related Complications
Table 26.1: Procedures to Manage Peripheral and Central Extravasations
Table 26.2: Common Vesicant and Irritant Drugs and Potential Antidotes
Table 26.3: Sample Standing Orders for Hypersensitivity Reactions to Chemotherapy Agents
Table 26.4: Infusion Reactions: The Comparison of Chemotherapy and Biotherapy Agents
Table 26.5: Sample Carboplatin Skin Testing Protocol
Table 26.6: Emetogenic Potential for Commonly Used Intravenous and Oral Chemotherapeutic Agents*
Table 26.7: Agents Used for Chemotherapy-Induced Nausea and Vomiting
Table 26.8: Examples of Regimens for Antiemetic Prevention and Management of Chemotherapy-Induced Nausea and Vomiting
III. Other Short-Term Complications Related to Cancer Chemotherapy
Table 26.9: Pharmacologic Management Strategies for Diarrhea
Table 26.10: Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia) Grading Scale
References
Chapter 27: Side Effects of Immune Therapy
I. Introduction
II. Systemic Effects
III. Cardiac Effects
IV. Hematologic Toxicity
V. Hepatic Toxicity
VI. Diarrhea/Colitis
VII. Endocrine Side Effects
VIII. Ocular Toxicity
IX. Neurologic Toxicity
X. Pulmonary Toxicity
XI. Other Organs
XII. Combination Studies of Ipilimumab and Nivolumab
XIII. Summary
References
Section Iv: Chemotherapeutic and Molecular Targeted Agents and Their Use
Chapter 28: Classification, Use, and Toxicity of Clinically Useful Chemotherapy and Molecular Targeted Therapy
I. Classes of Drugs
Table 28.1: Classification of Classical and Molecular Targeted Agents
II. Clinically Useful Chemotherapeutic, Biologic, and Moleculartargeted Agents
Table 28.2: Dose Modifications for Myelosuppressive Drugs With a Nadir* at Less than 3 Weeks
III. Data for Clinically Useful Chemotherapeutic, Biologic, and Molecular Targeted Agents